Show simple item record

dc.contributor.authorDíez-Alonso, Manuel
dc.contributor.authorMendoza-Moreno, Fernando
dc.contributor.authorJiménez-Álvarez, Laura
dc.contributor.authorNuñez, Oscar 
dc.contributor.authorBlazquez-Martín, Alma
dc.contributor.authorSanchez-Gollarte, Ana
dc.contributor.authorMatías-García, Belén
dc.contributor.authorMolina, Raquel
dc.contributor.authorSan-Juan, Alberto
dc.contributor.authorGutierrez-Calvo, Alberto
dc.date.accessioned2021-05-23T17:13:20Z
dc.date.available2021-05-23T17:13:20Z
dc.date.issued2021-05
dc.identifier.citationMol Clin Oncol. 2021 May;14(5):93.es_ES
dc.identifier.issn2049-9450es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/12992
dc.description.abstractThe aim of the present study was to identify predictive parameters of survival in patients affected by stage IV colorectal cancer with synchronous and bilateral liver metastases. A retrospective cohort study was performed. Patients diagnosed between January 2013 and December 2018 were included in the present study. Data on the histopathological, clinical and treatment factors (chemotherapy as the first measure or resection of the primary tumor) were collected. The effect of each variable on survival was evaluated using Cox regression analysis. A total of 104 patients were included [43 women (41.3%) and 61 men (58.7%); mean age, 63 years]. The long-term survival rate at 36 months was 29% (median, 25 months). Kaplan-Meier analysis was used to estimate that survival was higher in patients with wild-type KRAS tumors (42%) than in patients with mutated KRAS tumors (9%; P=0.001). In the multivariate analysis, KRAS mutation (HR, 2.484; 95% CI, 1.472-4.192), T4 tumors (HR, 1.795; 95% CI, 1.045-3.084), resection/local treatment of hepatic metastases (HR, 0.447; 95% CI, 0.222-0.901), Eastern Cooperative Oncology Group performance status (HR, 1.632; 95% CI, 1.182-2.254), were revealed to have independent predictive value. The type of treatment (chemotherapy or resection of the primary tumor) did not influence the survival. The results indicated that mutation of the KRAS gene was an important prognostic factor and associated with survival.es_ES
dc.language.isoenges_ES
dc.publisherSpandidos Publicationses_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectKRASes_ES
dc.subjectchemotherapyes_ES
dc.subjectcolorectal canceres_ES
dc.subjecthepatic metastasises_ES
dc.subjectsurvivales_ES
dc.titlePrognostic factors of survival in stage IV colorectal cancer with synchronous liver metastasis: Negative effect of the KRAS mutation.es_ES
dc.typeArtículoes_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID33767862es_ES
dc.format.volume14es_ES
dc.format.number5es_ES
dc.format.page93es_ES
dc.identifier.doi10.3892/mco.2021.2255es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3892/mco.2021.2255es_ES
dc.identifier.journalMolecular and Clinical Oncologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional